Polarization-controlled leakage current and photovoltaic effect in highly preferentially oriented BiFeO3 film

Highly preferentially oriented polycrystalline BiFeO₃ thin film was grown on FTO/glass substrate by a sol–gel method annealed at 500 °C. XRD result showed that the film adopts highly (100) preferential orientation. SEM results indicate that the film is composed of large grains of 40–200 nm and the thickness is about 320 nm. Room temperature saturated polarization and large Pr ~55 μC/cm² were obtained. Leakage current was substantially reduced by the controlling of ferroelectric polarization. Polarization-modulated conduction mechanism was studied. Moreover, substantial photovoltaic effect was observed.     

Phase‐Junction Electrocatalysts towards Enhanced Hydrogen Evolution Reaction in Alkaline Media

To ensure sustainable hydrogen production by water electrolysis, robust, earth‐abundant, and high‐efficient electrocatalysts are required. Constructing a hybrid system could lead to further improvement in electrocatalytic activity. Interface engineering in composite catalysts is thus critical to determine the performance, and the phase‐junction interface should improve the catalytic activity. Here, we show that nickel diphosphide phase junction (c‐NiP₂/m‐NiP₂) is an effective electrocatalyst for hydrogen production in alkaline media. The overpotential (at 10 mA cm^?2) for NiP₂‐650 (c/m) in alkaline media could be significantly reduced by 26 % and 96 % compared with c‐NiP₂ and m‐NiP₂, respectively. The enhancement of catalytic activity should be attributed to the strong water dissociation ability and the rearrangement of electrons around the phase junction, which markedly improved the Volmer step and benefited the reduction process of adsorbed protons.     

Mo的引入方式对CeO2脱硝性能的影响

固定源排放的氮氧化物(NOx)导致了严重的环境污染问题,NH3选择性催化还原(NH3-SCR)被认为是目前控制NOx排放的最有效技术,已广泛应用于电力行业的烟气排放治理.然而,我国非电行业的NOx减排仍然面临着重大挑战,因为其排放的废气温度通常低于300oC,且含有一定量的SO2,传统的钒基SCR催化剂因活性温度(300～400oC)较高而无法有效发挥作用.因此,亟待开发新型的高效低温SCR催化剂.铈基催化剂由于氧化铈(CeO2)的优异储氧能力(OSC)和良好的氧化还原能力而显示出较好的低温(80～300oC)脱硝性能,如Mn-Ce,W-Ce,Ta-Ce,Cu-Ce和Nb-Ce等.但这些铈基催化剂易被烟气中的SO2毒化而导致催化活性降低.因此,提高铈基SCR催化剂抗硫中毒能力是其产业化应用的关键.已有研究发现,通过构筑结构保护层或添加另一种金属来保护活性组分是提高SCR催化剂抗硫性能的一种可行策略.氧化钼(MoO3)通常被用做传统V2O5/TiO2催化剂的促进剂以提高其水热稳定性和表面酸性.研究表明,在V/Ti催化剂中引入钼物种不仅可以提高其SCR活性,而且提高了V/Ti催化剂的抗SO2性能,这是由于VMo/Ti表面较少的V–O–V键削弱了对SO2的氧化作用.Tang等开发了一种Fe2O3/MoO3纳米片催化剂,显示出比纯Fe2O3更好的抗SO2能力,主要是由于层状结构的MoO3能阻止NH4+在硫酸氢铵中的沉积.目前关于Mo的引入方式即催化剂的制备方法对铈基催化剂物化性能和NH3-SCR催化性能(特别是抗SO2能力)的影响的研究还比较少.本文分别采用浸渍法和沉淀法在CeO2中引入钼物种,制备了Mo-CeO2和MoCe-cp催化剂来探究制备方法对MoCe催化剂的脱硝性能及抗SO2中毒能力的影响.结果表明,引入Mo可以显著地提高CeO2的低温脱硝性能,其中Mo-CeO2催化剂在150 oC即可达到80％以上的脱硝效率,同时抗SO2中毒性能也得到了显著提高.对催化剂结构、氧化还原能力、表面酸度和反应物分子的吸附脱附性质进行了表征,并与MoCe催化剂脱硝性能和抗硫性能相关联.结果表明,Mo-CeO2和MoCe-cp催化剂的物理化学性质和脱硝性能有明显区别.首先,Mo-CeO2中的钼物种主要存在于CeO2表面,而MoCe-cp中的钼物种主要存在于CeO2体相,其为Mo-CeO2表面带来大量的Br?nsted酸位并抑制了硝酸盐的吸附,促使NH3-SCR反应按照Eley-Rideal机理进行,进而表现出优于MoCe-cp的低温活性.其次,Mo-CeO2表面更多的Mo物种抑制了SO2的吸附,从而使Mo-CeO2表现出更好的抗SO2性能.本文为具有实际应用前景的铈基NH3-SCR催化剂的设计提供了参考.     

轴对称弹性体扭转问题的无网格自然邻接点Petrov-Galerkin法

本文将无网格自然邻接点Petrov-Galerkin 法应用于轴对称弹性体扭转问题的求解．无网格自然邻接点Petrov-Galerkin 法采用自然邻接点插值构造试函数，并且采用三角形线性单元的形函数作为加权残值法的加权函数．自然邻接点插值构造的试函数满足Kronecker delta 函数性质，因此本质边界条件的施加十分方便．由于几何形状和边界条件的轴对称特点，原来的空间问题简化为二维问题求解，因此计算时只需要横截面上离散节点的信息．数值算例结果表明，所提出的方法对求解轴对称弹性体扭转问题是行之有效的．     

Carbon Dots as a New Class of Diamagnetic Chemical Exchange Saturation Transfer (diaCEST) MRI Contrast Agents

While carbon dots (C‐dots) have been extensively investigated pertaining to their fluorescent, phosphorescent, electrochemiluminescent, optoelectronic, and catalytic features, their inherent chemical exchange saturation transfer magnetic resonance imaging (CEST MRI) properties are unknown. By virtue of their hydrophilicity and abundant exchangeable protons of hydroxyl, amine, and amide anchored on the surface, we report here that C‐dots can be adapted as effective diamagnetic CEST (diaCEST) MRI contrast agents. As a proof‐of‐concept demonstration, human glioma cells were labeled with liposomes with or without encapsulated C‐dots and implanted in mouse brain. In vivo CEST MRI was able to clearly differentiate labeled cells from non‐labeled cells. The present findings may encourage new applications of C‐dots for in vivo imaging in deep tissues, which is currently not possible using conventional fluorescent (near‐infrared) C‐dots.     

Development of Zinc‐Specific iCEST MRI as an Imaging Biomarker for Prostate Cancer

The healthy prostate contains the highest concentration of mobile zinc in the body. As this level decreases dramatically during the initial development of prostate cancer, in vivo detection of prostate zinc content may be applied for diagnosis of prostate cancer. Using ¹⁹F ion chemical exchange saturation transfer magnetic resonance imaging (iCEST MRI) and TF‐BAPTA as a fluorinated Zn‐binding probe with micromolar sensitivity, we show that iCEST MRI is able to differentiate between normal and malignant prostate cells with a 10‐fold difference in contrast following glucose‐stimulated zinc secretion in vitro. The iCEST signal decreased in normal prostate cells upon downregulation of the ZIP1 zinc transporter. In vivo, using an orthotopic prostate cancer mouse model and a transgenic adenocarcinoma of the mouse prostate (TRAMP) model, a gradual decrease of >300 % in iCEST contrast following the transition of normal prostate epithelial cells to cancer cells was detected.     

Development of BCPDA-Eu3+-BAS Labeled Hepatitis B Surface Antibodies

The effect of the chelating agent 4,7-bis(chlorosulfophenyl)-1,10-phenanthroline-2,9-dicarboxylic acid (BCPDA) labeled hepatitis B surface antibodies(HBsAb) on time-resolved fluoroimmunoassays(TRFIA) was investigated. The labeling detection method was established. The biotin-streptavidin(BAS) system was introduced, and the multi-stage amplification effect of the BAS system was analyzed. It is found that the BCPDA-Eu³⁺-HBsAb-BAS fluorescent marker can emit strong fluorescence. Compared to BCPDA-Eu³⁺-HBsAb, BCPDA-Eu³⁺-HBsAb-BAS demonstrates an enhanced fluorescence intensity by over 10 times. This study provides a guidance for the next gene- ration non-radio immunoassays in clinical diagnosis.